Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders

Journal of Clinical Oncology

Volumn 36, Issue 19, 2018, Pages 1905-1912

  Leonardi, Giulia C ^a   Gainor, Justin F ^b   Altan, Mehmet ^d   Kravets, Sasha ^a   Dahlberg, Suzanne E ^a   Gedmintas, Lydia ^c   Azimi, Roxana ^b   Rizvi, Hira ^e   Riess, Jonathan W ^g   Hellmann, Matthew D ^e,f   Awad, Mark M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FILGRASTIM; IMMUNOMODULATING AGENT; MESALAZINE; NIVOLUMAB; PREDNISONE; PROGRAMMED DEATH 1 LIGAND 1 INHIBITOR; PROGRAMMED DEATH 1 RECEPTOR INHIBITOR; PROTEIN INHIBITOR; SALAZOSULFAPYRIDINE; STEROID; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ALOPECIA AREATA; ARTHRALGIA; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; CLINICAL FEATURE; COHORT ANALYSIS; CROHN DISEASE; DIABETES INSIPIDUS; DISCOID LUPUS ERYTHEMATOSUS; DISEASE EXACERBATION; DRUG WITHDRAWAL; FOLLOW UP; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NEPHRITIS; NON SMALL CELL LUNG CANCER; PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; RHEUMATIC FEVER; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SCLERODERMA; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; ULCERATIVE COLITIS; AGED; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CLINICAL TRIAL; FEMALE; IMMUNOLOGY; LUNG TUMOR; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; AUTOIMMUNE DISEASES; B7-H1 ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGRAMMED CELL DEATH 1 RECEPTOR; RETROSPECTIVE STUDIES;

EID: 85049019882     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.77.0305     Document Type: Article

References (15)

1. Brahmer J, Reckamp KL, Baas P, et al: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373: 123-135, 2015
2. Herbst RS, Baas P, Kim DW, et al: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 387:1540-1550, 2016
3. Reck M, Rodríguez-Abreu D, Robinson AG, et al: Pembrolizumab versus chemotherapy for PDL1-positive non-small-cell lung cancer. N Engl J Med 375:1823-1833, 2016
4. Rittmeyer A, Barlesi F, Waterkamp D, et al: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255-265, 2017
5. Langer CJ, Gadgeel SM, Borghaei H, et al: Carboplatin and pemetrexedwith orwithout pembrolizumab for advanced, non-squamous non-small-cell lung cancer: A randomised, phase 2 cohort of the openlabel KEYNOTE-021 study. Lancet Oncol 17:1497-1508, 2016
6. Borghaei H, Paz-Ares L, Horn L, et al: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373: 1627-1639, 2015
7. Antonia SJ, Villegas A, Daniel D, et al: Durvalumab after chemoradiotherapy in stage III non-smallcell lung cancer. N Engl J Med 377:1919-1929, 2017
8. Gettinger SN, Horn L, Gandhi L, et al: Overall survival and long-term safety of nivolumab (antiprogrammed death 1 antibody, BMS-936558, ONO-4538) in patientswith previously treated advanced nonsmall-cell lung cancer. J Clin Oncol 33:2004-2012, 2015
9. MetroG, Ricciuti B, Brambilla M, et al: The safety of nivolumab for the treatment of advanced non-small cell lung cancer. ExpertOpin Drug Saf 16:101-109, 2017
10. Khan SA, Pruitt SL, Xuan L, et al: Prevalence of autoimmune disease among patients with lung cancer: Implications for immunotherapy treatment options. JAMA Oncol 2:1507-1508, 2016
11. Franks AL, Slansky JE: Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res 32:1119-1136, 2012
12. Johnson DB, Sullivan RJ, Ott PA, et al: Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2:234-240, 2016
13. Menzies AM, Johnson DB, Ramanujam S, et al: Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28: 368-376, 2017
14. Nishino M, Giobbie-Hurder A, Hatabu H, et al: Incidence of programmed cell death 1 inhibitorrelated pneumonitis in patients with advanced cancer: A systematic review and meta-analysis. JAMA Oncol 2:1607-1616, 2016
15. Abdel-Wahab N, Shah M, Lopez-Olivo MA, et al: Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: A systematic review. Ann Intern Med 168:121-130, 2018